News & Announcements
PIC Therapeutics Completes $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer
Natick, Mass. – October 19, 2022 - PIC Therapeutics, Inc., a biopharmaceutical company dedicated to developing life-changing medicines for patients with cancer, today announced the closing of a $35 million Series A financing led by OrbiMed. Other new investors participating in this financing include Lumira Ventures and Harrington Discovery Institute. The company’s existing investors including Advent Life Sciences and Belinda Termeer also participated and provided initial seed financing instrumental to meeting key milestones.
PIC Therapeutics to Present Pre-Clinical Data on eIF4E Program to Address Breast Cancer Drug Resistance at AACR Annual Meeting 2022
PIC Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-mechanism, first-in-class allosteric therapies targeting eIF4E, today announced it will present pre-clinical data on the company’s eIF4E program for ER+ breast cancer in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022 in New Orleans, LA.
NATICK, MA – August 12, 2020 – PIC Therapeutics (“PIC”), a biotechnology company focused on transforming the treatment of cancer through the selective modulation of oncogene translation, today announced the appointment of Katherine Bowdish, Ph.D., as its President and Chief Executive Officer. Dr. Bowdish will also join the Board of Directors of PIC.
PIC Therapeutics Raises $5 Million to Advance Development of Small Molecules That Selectively Modulate eIF4E
BOSTON--(BUSINESS WIRE)--APRIL 15, 2020: PIC Therapeutics (“PIC”), a biotechnology company focused on transforming the treatment of cancer through the selective modulation of oncogene translation, closed a $5M Series Seed round of preferred equity funding.